Euroopa Liit - eesti - EMA (European Medicines Agency)

h. lundbeck a/s - eptinezumab - migreenihäired - valuvaigistid - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig  - tanezumab - osteoarthritis; pain - valuvaigistid - treatment of moderate to severe chronic pain associated with osteoarthritis (oa) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (nsaids) and/or any opioid is ineffective, not tolerated or inappropriate.